Pharmacokinetics of VP16-213 in Lewis lung carcinoma bearing mice

Tina Colombo, Massimo Broggini, Laura Torti, Eugenio Erba, Maurizio D'Incalci

Research output: Contribution to journalArticlepeer-review


The pharmacokinetics of VP16 have been investigated in Lewis lung bearing mice after i.v. doses of 13 and 40 mg/kg. At both doses the plasma elimination half-life was around 30 min. The lowest VP16-213 levels were in brain and primary tumor. Drug concentrations were much higher in metastases than in primary tumor. The highest concentrations were in small intestine, liver and kidney. Drug levels in the liver were disproportionally higher after 40 mg/kg, the AUC value being approximately 12 times greater than after 13 mg/kg. Urinary excretion of VP16-213 as unchanged drug accounted for 20-30% of the administered dose in the 60 h after treatment. The concentration cytotoxicity curve was very steep and apparently similar for cells derived from primary tumor or metastases grown in vitro.

Original languageEnglish
Pages (from-to)127-131
Number of pages5
JournalCancer Chemotherapy and Pharmacology
Issue number2-3
Publication statusPublished - 1982

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology


Dive into the research topics of 'Pharmacokinetics of VP16-213 in Lewis lung carcinoma bearing mice'. Together they form a unique fingerprint.

Cite this